Johnson & Johnson (JNJ) Free Cash Flow (2009 - 2026)
Johnson & Johnson's (JNJ) quarterly Free Cash Flow came in at $7.3 billion in Q2 2026, up 157.32% year-over-year from $2.8 billion in Q2 2025, and up 397.95% quarter-over-quarter from $1.5 billion in Q1 2026.
Analysis
Johnson & Johnson (JNJ) Free Cash Flow (2009 - 2026) Analysis & Trends
Johnson & Johnson has disclosed Free Cash Flow across 18 years of filings, most recently posting $7.3 billion for Q2 2026.
- In Q2 2026, Free Cash Flow rose 157.32% year-over-year to $7.3 billion; the TTM figure through Jun 2026 stood at $22.2 billion (up 19.92% YoY), while the FY2025 annual figure was $19.7 billion, down 0.73% from the prior year.
- Free Cash Flow came in at $7.3 billion for Q2 2026 at Johnson & Johnson, up from $1.5 billion in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of $8.0 billion in Q3 2025 to a low of $1.5 billion in Q1 2026.
- Average Free Cash Flow over 5 years is $4.5 billion, with a median of $4.0 billion recorded in 2024.
- Year-over-year, Free Cash Flow soared 259.75% in 2023 and plunged 56.64% in 2026.
- Over 5 years, Free Cash Flow stood at $3.4 billion in 2022, then jumped by 86.06% to $6.3 billion in 2023, then declined by 14.39% to $5.4 billion in 2024, then gained by 1.88% to $5.5 billion in 2025, then surged by 33.32% to $7.3 billion in 2026.
- Per Business Quant data, the three most recent Free Cash Flow figures were $7.3 billion in Q2 2026, $1.5 billion in Q1 2026, and $5.5 billion in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.65 Bn | 629.89 Bn | 17.26 Bn | 7.30 Bn |
| 2 | AbbVie | 466.34 Bn | 459.82 Bn | 12.70 Bn | 3.11 Bn |
| 3 | Merck | 362.11 Bn | 355.02 Bn | 12.21 Bn | 4.48 Bn |
| 4 | Novartis Ag | 267.81 Bn | 260.52 Bn | 11.24 Bn | 6.20 Bn |
| 5 | Pfizer | 157.31 Bn | 145.91 Bn | 10.94 Bn | 302.00 Mn |
| 6 | Bristol Myers Squibb | 128.75 Bn | 117.69 Bn | 9.25 Bn | 3.09 Bn |
| 7 | Sanofi | 51.80 Bn | 44.84 Bn | 10.79 Bn | 3.44 Bn |
| 8 | Revolution Medicines | 40.91 Bn | 40.91 Bn | - | -389.61 Mn |
| 9 | BeOne Medicines | 39.65 Bn | 34.55 Bn | 1.53 Bn | 437.80 Mn |
| 10 | Incyte | 25.18 Bn | 20.65 Bn | 1.57 Bn | 495.25 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 28, 2026 | 7.30 Bn |
| Mar 29, 2026 | 1.47 Bn |
| Dec 28, 2025 | 5.47 Bn |
| Sep 28, 2025 | 8.01 Bn |
| Jun 29, 2025 | 2.84 Bn |
| Mar 30, 2025 | 3.38 Bn |
| Dec 29, 2024 | 5.37 Bn |
| Sep 29, 2024 | 6.96 Bn |
| Jun 30, 2024 | 4.66 Bn |
| Mar 31, 2024 | 2.85 Bn |
| Dec 31, 2023 | 6.27 Bn |
| Oct 1, 2023 | 6.52 Bn |
| Jul 2, 2023 | 3.06 Bn |
| Apr 2, 2023 | 2.39 Bn |
| Jan 1, 2023 | 1.74 Bn |
| Apr 3, 2022 | 3.37 Bn |
| Oct 3, 2021 | 7.54 Bn |
| Jul 4, 2021 | 4.50 Bn |
| Apr 4, 2021 | 3.40 Bn |
| Jan 3, 2021 | 7.02 Bn |